Expansion into the High-Potency Pharmaceutical Sector
First written in FY2016. 8 of 14 entries say "Advanced", first in FY2017. Latest entry: 2026-07-15.
Daito Pharmaceutical moved to the "Worse" side of this theme in 2026.
0 other companies' latest entry also says "Worsened".
- 2026-07-15WorsenedFinancial results presentation
「Delay in some contract manufacturing of highly potent formulations」
A delay in some contract manufacturing of highly potent formulations is identified as a factor behind the revision of DTP2027 targets. - FY2025RestatedAnnual report
「The company is also taking steps such as focusing on the high-potency drug product sector, which is expected to grow within the generic drug market.」
It continues to state a policy of focusing on the high-potency drug product sector as a growth area in response to the generic drug market. - FY2022AdvancedAnnual report
「At Building 8, the company added a new production line, completed it in December 2020, and began commercial production in May 2022.」
For the new line at Building 8, it reports the specific progress of starting commercial production in May 2022 after completion in December 2020. - FY2020AdvancedAnnual report
「At Building 8, the company is expanding high-potency manufacturing equipment as a new production line.」
It states that, following completion of Building 8, the company is expanding a new high-potency manufacturing equipment line. - FY2019AdvancedAnnual report
「High-potency drug product manufacturing equipment 2,000,000 － Internal funds and borrowings from financial institutions December 2019 December 2020」
Following completion of Building 8, it describes a new plan for high-potency drug product manufacturing equipment costing ¥2 billion in total, with work scheduled to begin in December 2019 and completion scheduled for December 2020. - FY2019-Q3RestatedAnnual report
「The company built Building 8, a new manufacturing facility for high-potency solid dosage forms, and completed it in November 2018.」
It continues to report the completion of Building 8 in November 2018 as a manufacturing base for high-potency solid dosage forms. - FY2019-Q2AdvancedAnnual report
「The company built Building 8, a new manufacturing facility for high-potency solid dosage forms, and completed it in November 2018.」
It reports the specific progress that the planned Building 8 manufacturing facility for high-potency drug products was completed in November 2018. - FY2019-Q1RestatedAnnual report
「The company began construction of Building 8, a new manufacturing facility for high-potency solid dosage forms, in October 2017 and plans to complete it in November 2018.」
It reiterates the previous plan for Building 8, under which construction began in October 2017 and completion was scheduled for November 2018, without reporting any new progress. - FY2018AdvancedAnnual report
「As part of these efforts, following the completion in December 2014 of Building 7, which manufactures high-potency drug products at the head office site, the company built the High-Potency R&D Center, which develops and analyzes high-potency drug products and produces small lots of clinical trial drugs and other products, and completed it in June 2017. In addition, construction of Building 8, which manufactures high-potency drug products, began in October 2017, with completion scheduled for November 2018.」
Following completion of the High-Potency R&D Center, it reports the start of construction of Building 8 as completed progress and sets its planned completion for November 2018. - FY2018-Q3RestatedAnnual report
「Against this backdrop, the Group continues to strengthen its production platform and pursue active sales activities. Following the start of full-scale operations at the high-potency drug product manufacturing facility, Building 7, completed in December 2014, the High-Potency R&D Center, which develops and analyzes high-potency APIs and drug products and produces small lots of clinical trial drugs and other products, was completed in June 2017. In addition, construction of Building 8 on the head office plant site began in October 2017, with completion scheduled for December 2018.」
It describes the completion of the High-Potency R&D Center and the start of construction of Building 8, with completion scheduled for December 2018, as in the previous quarter, and indicates no new progress. - FY2018-Q2AdvancedAnnual report
「Against this backdrop, the Group continues to strengthen its production platform and pursue active sales activities. Following the start of full-scale operations at the high-potency drug product manufacturing facility, Building 7, completed in December 2014, the High-Potency R&D Center, which develops and analyzes high-potency APIs and drug products and produces small lots of clinical trial drugs and other products, was completed in June 2017. In addition, construction of Building 8 on the head office plant site began in October 2017, with completion scheduled for December 2018.」
For Building 8, progress has been made from the previous decision to build it and the planned construction start to the actual start of construction in October 2017. The completion schedule for December 2018 remains unchanged. - FY2018-Q1AdvancedAnnual report
「Following the start of full-scale operations at the high-potency drug product manufacturing facility, Building 7, completed in December 2014, the High-Potency R&D Center, which develops and analyzes high-potency APIs and drug products and produces small lots of clinical trial drugs and other products, was completed in June 2017. In addition, the company decided to build Building 8 on the head office plant site, with construction scheduled to begin in October 2017 and completion scheduled for December 2018.」
It reports the completion of the High-Potency R&D Center in June 2017 and adds the decision to build Building 8, with construction scheduled to begin in October 2017 and completion scheduled for December 2018. - FY2017AdvancedAnnual report
「The company built the High-Potency R&D Center, which develops and analyzes high-potency drug products and produces small lots of clinical trial drugs and other products, and completed it in June 2017. It also plans to begin construction of Building 8, which will manufacture high-potency drug products, during fiscal 2017.」
It reports the specific progress of the High-Potency R&D Center's completion in June 2017 and adds a plan to begin construction of Building 8 during fiscal 2017. - FY2016First statedAnnual report
「Following the completion in December 2014 of Building 7, which manufactures high-potency solid dosage forms at the head office site, the company plans to begin construction of a High-Potency R&D Center during fiscal 2016.」
The company has set out plans to establish a framework covering the manufacture of high-potency drug products, as well as the development and analysis of APIs and drug products and small-lot production of clinical trial drugs and other products.